Additionally, PBA-Niclo-SLNs significantly inhibited STAT3, TNBC stem cell populations (CD44+/CD24−), and EMT (epithelial–mesenchymal transition) markers along with increased tumor-site accumulation with significant tumor regression and enhanced survivability of TNBC-bearing mice [79]. The gene discussed is CD44; the disease is neoplasm.